Polymorphisms of matrix metalloproteinases in systolic heart failure: Role on disease susceptibility, phenotypic characteristics, and prognosis

Journal of Cardiac Failure

Volumn 17, Issue 2, 2011, Pages 115-121

  Velho, Fábio M ^a   Cohen, Carolina R ^a   Santos, Kátia G ^a,b   Silvello, Daiane ^a   Martinelli, Nidiane ^a   Biolo, Andréia ^a   Clausell, Nadine ^a   Rohde, Luis E ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Luteran University of Brazil   (Brazil)

Author keywords

Heart failure; metalloproteinases; polymorphism

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; OUTPATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; SYSTOLIC HEART FAILURE;

CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 79551683250     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.09.017     Document Type: Article

References (34)

1. R.C. Davis, F.D.R. Hobbs, and G.Y.H. Lip ABC of heart failure: history and epidemiology BMJ 320 2000 39 42
2. F.G. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ Res 90 2002 520 530
3. P.W.M. Fedak, S. Verma, R.D. Weisel, and R. Li Cardiac remodeling and failure: from molecules to man (Part II) Cardiovasc Pathol 14 2005 49 60 (Pubitemid 40381300)
4. E. Creemers, J. Cleutjens, J. Smits, and M. Daemen Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Circ Res 89 2001 201 210
5. F.G. Spinale Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle Eur Heart J 25 2004 631 633
6. A.J. White, S.J. Duffy, A.S. Walton, J.F. Ng, G.E. Rice, and S. Mukherjee Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease Cardiovasc Res 75 2007 813 820
7. S. Ye, P. Eriksson, A. Hamsten, M. Kurkinen, S.E. Humphries, and A.M. Henney Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression J Biol Chem 271 1996 13055 13060
8. L. Dunleavey, S. Beyzade, and S. Ye Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G 2G polymorphism that is associated with risk of cancer Matrix Biol 19 2000 175 177
9. S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome Cardiovasc Res 69 2006 636 645
10. S. Ye, C.R. Gale, and N. Martyn Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease Eur Heart J 24 2003 1668 1671
11. G. Ghilardi, M.L. Biondi, M. DeMonti, O. Turri, E. Guagnellini, and R. Scorza Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis Stroke 33 2002 2408 2412
12. T.N. Martin, D.E. Penney, J.A. Smith, B.A. Groenning, H.J. Dargie, and G.S. Hillis Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction Am J Cardiol 94 2004 1044 1046
13. L. Tang, X. Chen, M. Zhu, J.J. Jiang, X.B. Lu, and Y.X. Du Matrix metalloproteinase-1, -3 and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in Chinese Han population Clin Biochem 40 2007 1427 1430 (Pubitemid 350151431)
14. F. Mizon-Gerard, P. Groote, N. Lamblin, X. Hermant, J. Dallongeville, and P. Amouyel Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic failure according to the aetiology of left ventricular systolic dysfunction Eur Heart J 25 2004 688 693
15. W. Haberbosch, and A. Gardemann Gelatinase B C(-1562) T polymorphism in relation with ischemic heart disease Scand J Clin Lab Invest 65 2005 513 522
16. D.K. Lahiri, and J.I. Nurnberger A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies Nucleic Acids Res 19 1991 5444
17. L. Dunleavey, S. Beyzade, and S. Ye Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism Atherosclerosis 151 2000 587 589
18. B. Zhang, S. Ye, S.M. Herrmann, P. Eriksson, M. De Maat, and A. Evans Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis Circulation 99 1999 1788 1794
19. M. Stephens, and P. Scheet Accounting for decay of linkage disequilibrium in haplotype inference and missing data imputation Am J Human Genet 76 2005 449 462
20. M. Stephens, N.J. Smith, and P. Donnelly A new statistical method for haplotype reconstruction from population data Am J Human Genet 68 2001 978 979
21. P.W. Hedrick Gametic disequilibrium measures: proceed with caution Genetics 17 1987 331 341
22. J. D'Armiento Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction TCM 12 2002 97 101
23. R.T. Lee Matrix metalloproteinase inhibition and the prevention of heart failure TCM 11 2001 202 205
24. L.E. Felkin, E.J. Birks, R. George, S. Wong, A. Khaghani, and M.H. Yacoub A quantitative gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support J Heart Lung Transplant 25 2006 1413 1419
25. L.E. Rohde, A. Ducharme, L.H. Arroyo, M. Aikawa, G.H. Sukhova, and A. Lopez-Anaya Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice Circulation 99 1999 3063 3070
26. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinases inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210
27. V.L.N. Dalepiane, D.N. Silvello, C.A. Paludo, I. Roisenberg, and D. Simon Matrix metalloproteinase gene polymorphisms in patients with coronary artery disease Genet Mol Biol 30 2007 505 510
28. B.D. Horne, N.J. Camp, J.F. Carlquist, J.B. Muhlestein, M.J. Kolek, and Z.P. Nicholas Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease Am Heart J 154 2007 751 758
29. T. Nojiri, H. Morita, Y. Imai, K. Maemura, M. Ohno, and K. Ogasawara Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese Int J Cardiol 92 2003 181 186
30. O. De Winter, N. Van de Veire, F. Van Heuverswijn, G. Van Pottelberge, T.C. Gillebert, and J. De Sutter Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction Eur J Heart Fail 8 2006 275 277
31. M.N. Attar, K. Wong, D.G. Groves, N. Newall, D.R. Ramsdale, and R.K. Moore Clinical implications of QRS duration and QT peak prolongation in patients with suspected coronary disease referred for elective cardiac catheterization Ann Noninvasive Electrocardiol 13 2008 106 112
32. D.M. McNamara, S.W. Tam, M.L. Sabolinski, P. Tobelmann, K. Janosko, and L. Venkitachalam Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial J Card Fail 15 2009 191 198
33. A. Biolo, N. Clausell, K.G. Santos, R. Salvaro, P. Ashton-Prolla, A. Borges, and L.E. Rohde Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy Am J Cardiol 102 2008 726 732
34. D.M. McNamara, R. Holubkov, L. Postava, K. Janosko, G.A. MacGowan, and M. Mathier Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J Am Coll Cardiol 44 2004 2019 2026